Shots:
Rose received exclusive global rights to MannKind’s Technosphere tech to develop & commercialize ROSE-010 Technosphere, a rapid-acting GLP-1 receptor agonist, with initial work focused on formulation re-establishment & optimization, followed by nonclinical & regulatory development
MannKind will receive equity in Rose Pharma, the right to receive royalties on potential future net sales & board…
